Micotex

Quick links to important sections

Micotex

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micotex

Quick Facts

Property Description
Active ingredient Econazole nitrate
Form Cream, Solution, Foam
Pharmacological class Azole Antifungal / Antimycotic
Common use Management of fungal skin infections
Origin Synthetic (Imidazole derivative)

What is Micotex?

Micotex is a synthetic pharmaceutical preparation primarily classified as a topical antifungal medicine, designed to manage superficial fungal conditions on the skin. Its classification places it within the azole antifungal class, defining its basic chemical structure and mechanism of action against various fungi and yeasts.


What Type of Medicine is Micotex?

Micotex is classified as an antimycotic agent belonging to the azole antifungal family, distinguished by its single-active-ingredient product status and synthetic origin. Chemically, the drug is an imidazole derivative, a structure commonly found in compounds developed to interfere with fungal cell growth. Econazole is recognized as an essential medicine for managing fungal infections, reflecting its core therapeutic role.

A key differentiating feature of Econazole compared to many other azoles is the prescription-only status generally associated with its foam and cream formulations in major markets, which implies a higher level of medical supervision for its use compared to many over-the-counter options.


Composition and Form: What is Econazole Nitrate?

The sole active ingredient in Micotex is Econazole, typically incorporated as the salt Econazole nitrate, which provides the therapeutic effect. For targeted action, the medicine is prepared strictly for topical application and is available in several pharmaceutical preparations, most commonly a cream, a solution, and sometimes a specialized foam. Econazole is characterized by its penetration into the skin layers when applied topically, a feature relevant for treating various superficial infections. These forms utilize a suitable base or vehicle—such as a water-based cream matrix or a hydroalcoholic solution—to ensure the active compound is delivered effectively and concentrated directly at the site of the infection on the skin's surface.


What is the General Therapeutic Purpose of Micotex?

The general therapeutic purpose of Micotex is to manage and eliminate fungal overgrowth on the skin by a process known as ergosterol synthesis inhibition. This fundamental action involves disrupting ergosterol, a vital structural component of the fungal cell membrane, which subsequently renders the fungus incapable of growing or surviving. The resulting fungicidal (killing) and fungistatic (growth-inhibiting) effects allow the medicine to actively combat the cause of the infection.

Regulatory References

  1. WHO Model Lists of Essential Medicines

What side effects are possible with Micotex?

Possible Side Effects and Safety Information

The safety profile for Econazole nitrate, the active ingredient in Micotex, is primarily defined by localized application site reactions, as documented in official government labeling. Systemic absorption following topical use is officially noted to be low.

Officially Classified Adverse Reactions

The majority of side effects are classified under Skin and Subcutaneous Tissue Disorders or General Disorders and Administration Site Conditions in regulatory documents.

Frequency Classification Examples of Officially Documented Effects
Common (1% to 10%) Pruritus (Itching), Skin burning sensation, Erythema (Redness)
Uncommon (0.1% to 1%) Rash, Vulvovaginal burning sensation (for certain uses)
Not Known (Post-marketing) Hypersensitivity, Angioedema, Urticaria (Hives), Application site pain

Serious adverse reactions reported through post-marketing surveillance are rare but include hypersensitivity events such as angioedema.

Safety Considerations for Specific Groups

Official labeling includes specific constraints for certain populations, reflecting the regulatory assessment of risk:

  • Pregnancy (First Trimester): Avoidance is advised unless essential, according to regulatory caution statements.
  • Lactation: Caution is recommended as it is not known if the active substance is transferred into human milk.
  • Pediatric Use: The safety and effectiveness of the foam formulation have not been established in patients under 12 years of age.

Safety Restrictions and Warnings

Official regulatory documents note that the product is contraindicated for individuals with a known allergy or hypersensitivity to Econazole nitrate or any of the product’s excipients. A specific high-level drug interaction is documented, noting the potential for an enhanced anticoagulant effect when used concurrently with warfarin.

Overdose and Emergency Response

Micotex Overdose and when to seek help

The official regulatory profile for Micotex (Econazole nitrate) overdose is established within the context of its use as a topical medicine. Overdosage in humans has not been reported to date. This finding is consistent with the product’s intended application route, which results in minimal systemic absorption and a minimal risk of systemic overdose.


Documented Manifestations and Actions

The regulatory documents address potential adverse events only in the specific context of gross misuse, such as accidental oral ingestion of large amounts. The anticipated clinical presentation primarily involves effects on the gastrointestinal system. Symptoms that may follow accidental ingestion include nausea, vomiting, and diarrhoea.

No specific antidote for Econazole nitrate is described in the official labeling. Consequently, the management approach mandated by regulatory authorities focuses entirely on supportive measures.


When to Seek Urgent Help

If large amounts of the product have been taken by mouth or swallowed, immediate medical help is required to ensure appropriate supportive care and symptomatic therapy are initiated promptly. The official information does not specify different overdose manifestations or management requirements for particular populations or co-existing conditions.

Therapeutic Uses of Micotex

What Micotex Treats: Main Uses and Benefits

Micotex is commonly used in therapeutic domains involving certain distressing symptoms linked to superficial fungal infections. As a topical antifungal, it is applied across domains where additional symptomatic support is needed to address infections affecting the skin.

The category of medication to which Micotex belongs is relevant for easing symptoms that interfere with daily comfort across several conditions presenting with localized discomfort. The medication may assist with managing symptoms associated with acute or episodic changes that may be present during fungal conditions.

This product is considered relevant in situations involving fungal skin conditions such as athlete’s foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), and superficial infections caused by yeast (cutaneous candidiasis). The medication is applied in addressing conditions where functional stability becomes affected and supports patients during episodes of heightened discomfort.

“The product contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Supports Easing Physical Discomfort

Eligibility and Restrictions for Use

Micotex is contraindicated for individuals who have a known hypersensitivity or allergy to econazole nitrate or to any inactive ingredient found within the specific product formulation. This is the only listed absolute regulatory exclusion.

The official eligibility profile for this medicine is defined by specific limitations concerning age, physiological status, and application site, as summarized below:

Population Category Eligibility Status (Regulatory Wording)
Children < 12 Years Safety and efficacy have not been established.
Adolescents ge 12 Years Eligible for use with the topical foam formulation.
Geriatric ge 65 Years Clinical studies did not include sufficient numbers to determine differential response.
Pregnancy Use is conditional; restricted to when considered essential (first trimester) or clearly needed (second/third trimesters).
Nursing Mothers Caution must be exercised, as it is not known whether the drug is excreted in human milk.
Warfarin Users Use triggers a restriction requiring monitoring of INR due to potential enhancement of the anticoagulant effect.

This medication is for external use only and is strictly not for ophthalmic, oral, or intravaginal use. The official eligibility classifications are based on established safety data, lack of data, or documented risk constraints in specific patient groups, and are derived exclusively from authoritative government labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Econazole nitrate (Micotex) is derived from documented reports following its topical application. The official prescribing information identifies one primary interaction based on post-marketing experience.


Documented Drug–Drug Interaction

The most significant and formally described drug interaction is with Vitamin K Antagonists (VKAs), such as warfarin or acenocoumarol. This is classified as a pharmacodynamic interaction where the co-administration of topical Econazole may lead to an enhancement of the anticoagulant effect of the VKA.


Interaction Constraints and Monitoring

This interaction is linked to the increased systemic absorption of Econazole, which is dependent on how the product is applied. Regulatory documentation notes that the risk is heightened when the product is applied to large body surface areas, the genital area, or under occlusion.

For patients concurrently using Econazole and a VKA, official labels state that monitoring of laboratory parameters such as International Normalized Ratio (INR) or Prothrombin Time may be indicated.

Food, Alcohol, and Other Substances

Official regulatory documents do not document specific interactions between Econazole and food, alcohol, herbal products, or supplements. No mandatory timing or separation requirements for administration are formally listed in the prescribing information.

Mechanism of Action

Micotex (Econazole nitrate) works through a dual mechanistic approach that involves both action on the fungal cell structure and modulation of host inflammatory signaling.

Disrupting Fungal Cell Structure via Enzyme Inhibition

The primary mechanism involves acting as an inhibitor of the fungal enzyme lanosterol 14-alpha-demethylase (CYP51). This enzyme, a molecular target, is necessary for synthesizing ergosterol, a key structural lipid of the fungal cell membrane. The resulting blockage in the ergosterol biosynthesis pathway causes both a lack of vital structural components and the accumulation of toxic precursor sterols. This mechanistic cascade compromises the fungal cell's integrity and permeability.

Modulating Local Tissue Inflammatory Responses

A secondary, distinct mechanism involves the modulation of host inflammatory pathways. Econazole engages in the inhibition of key inflammatory mediators, such as prostaglandins and leukotrienes, in the local tissue environment. The subsequent reduction in these mediators limits the local tissue response, which influences the signaling dynamics within localized neurovascular pathways.

Dosage and Administration Information

How to Use Micotex (Econazole Nitrate)

Micotex is intended for topical (cutaneous) administration only. It must not be used orally, ophthalmically, or intravaginally. The medicine is available as a 1% cream and a 1% topical foam.


Official Dosing and Administration Patterns

Feature Administration Guideline
Application A sufficient amount of the product is gently rubbed into the affected area and surrounding skin.
Frequency Once daily for tinea pedis, tinea cruris, tinea corporis, and tinea versicolor. Twice daily (morning and evening) for cutaneous candidiasis.
Duration Treatment is generally required for a full two weeks for most indications, but up to four weeks for athlete's foot (tinea pedis).

Usage Constraints and Special Conditions

Specific conditions apply for proper use. The treatment course must be completed for the full prescribed duration. For the 1% foam formulation, use is indicated for patients 12 years of age and older. The foam preparation is classified as flammable; users should avoid heat, flame, and smoking during and immediately following application. In accordance with standard usage principles, if no clinical improvement is observed after the specified treatment period, the diagnosis should be formally reassessed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Micotex


Evidence for Use in Athlete’s Foot (Tinea Pedis)

Research concerning Micotex has focused extensively on studies examining its use for athlete’s foot, particularly the common type that occurs between the toes. Research explored this use primarily through rigorous, short-term Randomized Controlled Trials (RCTs). These studies were designed to monitor outcomes related to physical discomfort and acute changes in the skin, comparing the active Econazole nitrate formulation against an inactive base, or vehicle. Research reported the number of subjects who met a predefined "Complete Cure" outcome in the active formulation group compared to the inactive base group, which required both mycological clearance and complete symptom resolution.

Evidence for Ringworm (Tinea Corporis) and Jock Itch (Tinea Cruris)

Research for Micotex used in conditions like ringworm and jock itch was evaluated through a combination of older clinical trials and systematic reviews that explore the entire class of azole antifungal agents. These studies monitored outcomes related to clearing the fungal organism (mycological cure) and the assessed clinical state of the skin condition. However, the evidence quality varies across studies; systematic reviews often rate the methodological rigor of some older trials as being low.

Long-Term Studies and Follow-up

Limited information is available for long-term outcomes. The majority of pivotal research for Micotex focused on short-term symptom changes, with most clinical trials monitoring responses over defined time intervals that lasted only a few weeks beyond the end of treatment. Therefore, the long-term effects are not fully established, and there is limited information regarding the durability of the response or the frequency of disease relapse over many months or years.

Evidence in Special Populations

Research has explored the use of Micotex in a limited range of populations. Most high-quality studies have included adolescents (age 12) and the general adult population. Data for certain groups remain insufficient, including a lack of sufficient dedicated research examining outcomes in older adults or individuals with complex, comorbidity-defined groups. Formal clinical trials focused on pregnant or breastfeeding populations are not readily available in the primary evidence base.

Frequently Asked Questions (FAQ)

Common questions about Micotex (FAQ)


Q: How long does Micotex stay in the body after the last use?

The official product information states that Micotex (econazole nitrate) is designed for topical use. As a result, its absorption into the body's system is considered extremely low.

This low absorption is a documented pharmacological property of the topical medicine.


Q: Does long-term use of Micotex increase the risk of side effects?

Official studies have focused on the typical short-term use required for treatment. Regulatory documents note that dedicated long-term studies to determine the potential for cancer, for example, have not been performed using the drug.

Therefore, data on the risk profile for extended use is limited.


Q: Why does the treatment duration for Micotex vary greatly between different infections?

The varying treatment durations are set based on clinical trials to align with the objective of eliminating the infection and minimizing the chance of recurrence.

For instance, the treatment time for athlete's foot (tinea pedis) is typically longer (4 weeks) than for many other types of fungal infections (2 weeks), reflecting the specific needs of clearing the fungus in those areas.


Q: How quickly does Micotex usually start to work?

Official documents indicate that most patients experience early relief of symptoms after starting treatment.

While the full course must be completed, clinical improvement may be observed fairly soon after the medicine is applied.


Q: What is the typical timeframe before an improvement might be noticed?

According to the product information, patients may notice clinical improvement fairly soon after starting Micotex.

However, the treatment course must be completed for the entire duration prescribed, even if the skin appears better, to align with the objective of eliminating the infection.


Q: Can Micotex cause stomach upset or digestive problems?

The most commonly reported side effects are localized to the area of application, such as itching or a burning sensation on the skin.

Since Micotex is minimally absorbed into the body, systemic effects like stomach upset or digestive problems are not listed among the common or less common reported side effects.


Q: Is a headache a common side effect when taking Micotex?

Official labeling does not list headache as one of the common side effects that occur in 1% to 10% of users.

Clinical trial data has occasionally noted headache in a small percentage of people, but it is not one of the primary adverse reactions associated with the use of Micotex.


Q: Does Micotex affect blood sugar levels?

Official labeling does not list changes in blood sugar (blood glucose) levels as a known or common adverse reaction.

While a single instance of increased blood glucose was noted in the placebo group during a clinical trial, this is not documented as a common or known side effect in the official label.


Q: Can Micotex be taken if a person has heart problems?

Official regulatory documents do not list heart problems as a contraindication or required precaution for using Micotex.

The product is minimally absorbed into the body, which generally limits systemic impact.


Q: Does Micotex interact with common pain relievers like ibuprofen or acetaminophen?

The official label explicitly documents an interaction only with a specific type of blood thinner called Vitamin K Antagonists (like warfarin).

Regulatory documents do not list or document specific interactions between Micotex and common over-the-counter pain relievers such as ibuprofen or acetaminophen.


Q: Are there any widely reported interactions between Micotex and cholesterol medications?

The only specific drug interaction formally described in regulatory documents is with Vitamin K Antagonists (like warfarin).

Official product information does not document any specific interactions with cholesterol-lowering medications.


Q: Can Micotex be used at the same time as cold and flu medicines?

Official labeling indicates that the only drug interaction formally documented is with warfarin and other Vitamin K Antagonists.

The product label does not list any specific precaution or required monitoring related to general cold and flu medicines.


Q: Does Micotex interact with oral contraceptives or birth control pills?

The official label documents an interaction only with Vitamin K Antagonists (like warfarin).

Regulatory documentation does not contain information describing specific interactions with oral contraceptives or birth control pills.


Q: What happens if a person occasionally misses using Micotex?

According to the patient information guidance, official guidance recommends applying the product as soon as it is remembered. However, if it is nearly time for the next scheduled application, the guidance specifies that the missed dose is skipped.

It is important not to apply a double amount to compensate for the skipped application, and the patient guidance directs users to continue with the regular schedule.


Q: What is the difference between brand-name Micotex and its generic equivalent?

Generic and brand-name formulations contain the same active ingredient, econazole nitrate, and are required to meet the same federal standards for strength and purity.

The main differences are typically in the inactive ingredients used in the cream or foam base, and potentially the cost.


Q: Does Micotex affect a person's ability to drive or operate machinery?

Official regulatory documents do not list specific restrictions or warnings regarding driving or operating machinery.

This is consistent with the drug's nature as a topical product with extremely low systemic absorption; due to its extremely low absorption, it is not generally associated with effects that impair driving.


Q: Can taking Micotex cause dizziness or change vision?

Dizziness or changes in vision are not listed among the common or uncommon side effects in the official labeling.

Since the medicine is absorbed very little into the body, the risk of systemic adverse effects is considered low, consistent with the minimal absorption.


Q: Can Micotex affect a person's mood or cause changes in behavior?

Official regulatory documents do not list changes in mood or behavior as known adverse reactions associated with the medicine.

Because Micotex is for topical application, psychiatric side effects are not listed in the adverse reactions section, consistent with its low systemic absorption.

How should Micotex be stored and disposed of?

How to Store and Dispose of Micotex (Econazole Nitrate)

Official regulatory documents define strict conditions for storing and disposing of Micotex to maintain its stability and ensure safety.

Item Requirement
Temperature Store at controlled room temperature (20^circ to 25 C or 68^circ to 77 F); do not freeze or store above 30 C (86 F).
Protection Protect the medicine from heat and moisture.
Packaging Keep in the original container and ensure the tube is tightly closed.
Child Safety Must be kept out of the sight and reach of children.
Disposal Do not dispose of unused or expired product via wastewater or household waste; return it to a pharmacy or designated collection point according to local regulations.

These storage conditions are mandatory to preserve the product's integrity. Disposal rules require environmentally responsible handling, instructing that unused portions be returned rather than discarded in the trash or flushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Micotex found in:

A-Z Index: